Xbiotech Stock Today
| XBIT Stock | USD 3.82 0.02 0.53% |
Performance0 of 100
| Odds Of DistressLess than 10
|
XBiotech is selling for under 3.82 as of the 18th of January 2025; that is 0.53 percent increase since the beginning of the trading day. The stock's last reported lowest price was 3.8. XBiotech has less than a 10 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 19th of December 2024 and ending today, the 18th of January 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 15th of April 2015 | Category Healthcare | Classification Health Care |
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company was incorporated in 2005 and is headquartered in Austin, Texas. Xbiotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 30.48 M outstanding shares of which 770.65 K shares are at this time shorted by private and institutional investors with about 7.63 trading days to cover. More on XBiotech
Moving against XBiotech Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
XBiotech Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
XBiotech (XBIT) is traded on NASDAQ Exchange in USA. It is located in 5217 Winnebago Lane, Austin, TX, United States, 78744 and employs 82 people. XBiotech is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 116.45 M. XBiotech conducts business under Biotechnology sector and is part of Health Care industry. The entity has 30.48 M outstanding shares of which 770.65 K shares are at this time shorted by private and institutional investors with about 7.63 trading days to cover.
XBiotech currently holds about 225.79 M in cash with (18.73 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.42, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check XBiotech Probability Of Bankruptcy
Ownership AllocationXBiotech retains a total of 30.48 Million outstanding shares. XBiotech owns significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company shows, if the real value of the entity is less than the current market value, you may not be able to make money on it.
Check XBiotech Ownership Details
XBiotech Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Connor Clark & Lunn Inv Mgmt Ltd | 2024-09-30 | 75.7 K | |
| Dimensional Fund Advisors, Inc. | 2024-09-30 | 72.5 K | |
| Empowered Funds, Llc | 2024-09-30 | 62.6 K | |
| Charles Schwab Investment Management Inc | 2024-09-30 | 58.4 K | |
| Goldman Sachs Group Inc | 2024-09-30 | 40.4 K | |
| Bnp Paribas Arbitrage, Sa | 2024-09-30 | 40 K | |
| Fmr Inc | 2024-09-30 | 29 K | |
| Barclays Plc | 2024-09-30 | 26.3 K | |
| Nuveen Asset Management, Llc | 2024-09-30 | 24.9 K | |
| Blackrock Inc | 2024-09-30 | 1.3 M | |
| Vanguard Group Inc | 2024-09-30 | 1.1 M |
XBiotech Historical Income Statement
XBiotech Stock Against Markets
XBiotech Corporate Management
| Benjamn Guzmn | Sr Fin | Profile | |
| Angela Hu | Principal Finance | Profile | |
| Lisa Simard | Inc USA | Profile | |
| Sushma Shivaswamy | Chief Officer | Profile | |
| BA CGA | VP Sec | Profile |
Already Invested in XBiotech?
The danger of trading XBiotech is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of XBiotech is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than XBiotech. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile XBiotech is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for XBiotech Stock Analysis
When running XBiotech's price analysis, check to measure XBiotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XBiotech is operating at the current time. Most of XBiotech's value examination focuses on studying past and present price action to predict the probability of XBiotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XBiotech's price. Additionally, you may evaluate how the addition of XBiotech to your portfolios can decrease your overall portfolio volatility.